Molecular pathogenesis of chronic myeloid leukemia: Implications for new therapeutic strategies

Annals of Hematology

Volumn 78, Issue 2, 1999, Pages 49-64

  Warmuth, M ^a   Danhauser Riedl, S ^a   Hallek, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

bcr abl; Chronic myeloid leukemia; Philadelphia translocation; Signal transduction

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTOKINE RECEPTOR; GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; STAT1 PROTEIN;

BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CANCER INCIDENCE; CELL ADHESION; CELL TRANSFORMATION; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; HEMATOPOIESIS; HUMAN; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE RAS; ONCOGENE SRC; PATHOGENESIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BLAST CRISIS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL ADHESION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; FIBROBLASTS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, ABL; GROWTH SUBSTANCES; GUANINE NUCLEOTIDES; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICE; MICE, SCID; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PHILADELPHIA CHROMOSOME; PHOSPHOPROTEINS; PROTEINS; RAS PROTEINS; RATS; RECEPTORS, CYTOKINE; RECEPTORS, GROWTH FACTOR; RETINOBLASTOMA-LIKE PROTEIN P130; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 0033003074     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050473     Document Type: Review

References (186)

1. Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL (1994) Differential complementation of Bcr-Abl point mutants with c-Myc. Science 264:424-426
2. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ (1989) Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci U S A 86:6783-6787
3. Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky WE (1996) Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol 95:501-507
4. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR (1998) Bcl-2-independent BerAbl-mediated resistance to apoptosis: protection is correlated with upregulation of Bcl-xL. Oncogene 16:1383-1390
5. Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY (1995) Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 91:387-393
6. Andreeff M (1986) Cell kinetics of leukemia. Semin Hematol 23:300-314
7. Barbacid M (1987) ras genes. Annu Rev Biochem 56:779-827
8. Barber DL, Mason JM, Fukazawa T, Reedquist KA, Druker BJ, Band H, D'Andrea AD (1997) Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood 89:3166-3174
9. Barila D, Superti-Furga G (1998) An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 18:280-282
10. Barone MV, Courtneidge SA (1995) Myc but not Fos rescue of PDGF signaling block caused by kinase-inactive Src. Nature 378:509-512
11. Bedi A, Zehnbauer DA, Barber JP, Sharkis SJ, Jones RJ (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038-2044
12. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia-specific p210 protein is the product of the bcr/abl hybrid gene. Science 233:212-214
13. Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ (1997) Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells. J Biol Chem 272:16170-16175
14. Bhatia R, Verfaillie CM (1998) The effect of interferon-alpha on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia. Leuk Lymphoma 28:241-254
15. Brown MT, Cooper JA (1996) Regulation, substrates and functions of src. Biochim Biophys Acta 1287:121-149
16. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG (1998) BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 16:335-348
17. Carlesso N, Frank DA, Griffin JD (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183:811-820
18. Carpenter CL, Cantley LC (1996) Phosphoinositide kinases. Curr Opin Cell Biol 8:153-158
19. Carpino N, Wisniewski D, Strife A, Marshak D, Kobayashi R, Stillman B, Clarkson B (1997) p62dok: a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 88:197-204
20. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood 90:4947-4952
21. Carter AN, Downes CP (1992) Phosphatidylinositol 3-kinase is activated by nerve growth factor and epidermal growth factor in PC12 cells. J Biol Chem 267:14563-14567
22. Chuang TH, Xu X, Kaartinen V, Heisterkamp N, Groffen J, Bokoch GM (1995) Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. Proc Natl Acad Sci U S A 92:10282-10286
23. Cicchetti P, Mayer BJ, Thiel G, Baltimore D (1992) Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. Science 257:803-806
24. Clark BR, Gallagher JT, Dexter TM (1992) Cell adhesion in the stromal regulation of haemopoiesis. Baillieres Clin Haematol 5:619-652
25. Clarkson B, Strife A (1993) Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 7:1683-1721
26. Cooper JA, MacAuley A (1988) Potential positive and negative autoregulation of p60c-src by intermolecular autophosphorylation. Proc Natl Acad Sci U S A 85:4232-4236
27. Cortez D, Kadlec L, Pendergast AM (1995) Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15:5531-5541
28. Cortez D, Stoica G, Pierce JH, Pendergast AM (1996) The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 13:2589-2594
29. Cortez D, Reuther G, Pendergast AM (1997) The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15:2333-2342
30. Coughlin SR, Escobedo JA, Williams LT (1989) Role of phosphatidylinositol kinase in PDGF receptor signal transduction. Science 243:1191-1194
31. Coulombel L, Auffray I, Gaugler MH, Rosemblatt M (1997) Expression and function of integrins on hematopoietic progenitor cells. Acta Haematol 97:13-21
32. Dai Z, Pendergast AM (1995) Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev 9:2569-2582
33. Daley GQ, Baltimore D (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210bcr/abl protein. Proc Natl Acad Sci USA 85:9312-9316
34. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830
35. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M (1996) Activation of Src kinases p53/56lyn and p59hck by p210bcr-abl in myeloid cells. Cancer Res 56:3589-3596
36. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR (1994) The ins and outs of Raf kinases. Trends Biochem Sci 19:474-480
37. Deininger MW, Goldman JM, Lydon N, Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698
38. de Jong R, ten Hoeve J, Heisterkamp N, Groffen J (1995) CRKL is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 270:21468-21471
39. de Jong R, van Wijk A, Haataja L, Heisterkamp N, Groffen J (1997) BCR/ABL-induced leukemogenesis causes phosphorylation of Hefl and its association with Crkl. J Biol Chem 272:32649-32655
40. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ (1997) A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277:693-696
41. Di Cristofano A, Carpino N, Dunant N, Friedland G, Kobayashi R, Strife A, Wisniewski D, Clarkson B, Pandolfi PP, Resh MD (1998) Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins. J Biol Chem 273:4827-4830
42. Downward J (1996) Control of Ras activation. In: Parker P, Pawson T (eds) Cell signalling. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 87-100
43. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566
44. Elefanty AG, Hariharan IK, Cory S (1990) Bcr-Abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 9:1069-1078
45. Franz WM, Berger P, Wang JY (1989) Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J 8:137-147
46. Fukui Y, Hanafusa H (1989) Phosphatidylinositol kinase activity associates with viral p60src protein. Mol Cell Biol 9:1651-1658
47. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, Greinix H, Mannhalter C, Haas OA, Lechner K, et al (1995) Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 86:2371-2378
48. Gesbert F, Garbay C, Bertoglio J (1998) Interleukin-2 stimulation induces tyrosine phosphorylation of p120-Cbl and CrkL and formation of multimolecular signaling complexes in T lymphocytes and natural killer cells. J Biol Chem 273:3986-3993
49. Gishizky ML, Witte ON (1992) Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 256:836-839
50. Gishizky ML, Cortez D, Pendergast AM (1995) Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci U S A 92:10889-10893
51. Goga A, Liu X, Hambuch TM, Senechal K, Major E, Berk AJ, Witte ON, Sawyers CL (1995) p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase. Oncogene 11:791-799
52. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON (1995) Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82:981-988
53. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG (1996) Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 16:4107-4116
54. Gordon MY, Dowding CR, Riley GP, Goldman JM, Graeves MF (1989) Adhesive defects in chronic myeloid leukemia. Curr Top Microbiol Immunol 149:151-155
55. Gotoh A, Miyazawa K, Ohyashiki K, Toyama K (1994) Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3′-kinase. Leukemia 8:115-120
56. Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, Toyama K (1995) Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol 23:1153-1159
57. Greulich H, Hanafusa H (1996) A role for Ras in v-Crk transformation. Cell Growth Differ 7:1443-1451
58. Hallek M, Herbst R, Danhauser-Riedl S, Warmuth M, Winkler A, Kolb HJ, Druker BJ, Emmerich B, Griffin JD, Ullrich A (1996) Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol 94:5-16
59. Hariharan IK, Harris AW, Crawford M, Abud H, Webb E, Cory S, Adams JM (1989) A bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol 9:2798-2805
60. Harrison-Findik D, Susa M, Varticovski L (1995) Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells. Oncogene 10:1385-1391
61. Harte MT, Hildebrand JD, Burnham MR, Bouton AH, Parsons JT (1996) p130Cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase. J Biol Chem 271:13649-13655
62. Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S, Druker BJ (1997) Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 89:297-306
63. Heisterkamp N, Stam K, Groffen J (1985) Structural organization of the bcr gene and its role in the Ph1 translocation. Nature 315:758-761
64. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pottengale PK, Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344:251-253
65. Honda H, Fujii T, Takatoku M, Mano H, Witte ON, Yazaki Y, Hirai H (1995) Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood 85:2853-2861
66. Honda H, Oda H, Suzuki T, Takahashi T, Witte ON, Ozawa K, Ishikawa T, Yazaki Y, Hirai H (1998) Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. Blood 91:2067-2075
67. Hotchin NA, Hall A (1996) Regulation of the actin cytoskeleton, integrins and cell growth by the Rho family of small GTPases. In: Parker P, Pawson T (eds) Cell signalling. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, pp 311-324
68. Hu P, Margolis B, Skolnik EY, Lammers R, Ullrich A, Schlessinger J (1992) Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol 12:981-990
69. Hurley RW, McCarthy JB, Verfaillie CM (1995) Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest 96:511-519
70. Hurley RW, McCarthy JB, Wayner EA, Verfaillie CM (1997) Monoclonal antibody crosslinking of the alpha 4 or beta 1 integrin inhibits committed clonogcnic hematopoietic progenitor proliferation. Exp Hematol 25:321-328
71. Ilaria RL, Van Etten RA (1995) The SH2 domain of p210bcr/abl is not required for the transformation of hematopoetic factor-dependent cells. Blood 86:3897-3904
72. Ilaria RLJ, Van Etten RA (1996) P210 and P190(BCR/ ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271:31704-31710
73. Jackson P, Baltimore D (1989) N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J 8: 449-456
74. Jackson PK, Paskind M, Baltimore D (1993) Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. Oncogene 8:1943-1956
75. Jain SK, Susa M, Keeler ML, Carlesso N, Druker B, Varticovski L (1996) PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 88:1542-1550
76. Jain SK, Langdon WY, Varticovski L (1997) Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase. Oncogene 14:2217-2228
77. Jelinek T, Dent P, Sturgill TW, Weber MJ (1996) Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation. Mol Cell Biol 16:1027-1034
78. Kabarowski JHS, Allen PB, Wiedemann LM (1994) A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 13:5887-5895
79. Kipreos ET, Wang JYJ (1992) Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA. Science 256:382-385
80. Klucher KM, Lopez DV, Daley GQ (1998) Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression [in-process citation]. Blood 91:3927-3934
81. Konopka JB, Watanabe SM, Witte ON (1984) An alteration of the human c-Abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035-1042
82. Laneuville P, Timm M, Hudson AT (1994) bcr/abl expression in 32D c13(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res 54:1360-1366
83. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JYJ (1996) Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A 93:15174-15179
84. Liu J, Wu Y, Arlinghaus RB (1996) Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res 56:5120-5124
85. Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N, Groffen J, Arlinghaus RB (1996) Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol 16:998-1005
86. Liu X, Marengere LEM, Koch CA, Pawson T (1993) The v-Src SH3 domain binds phosphatidylinositol 3′-kinase. Mol Cell Biol 13:5225-5232
87. Lu D, Liu J, Campbell M, Guo JQ, Heisterkamp N, Groffen J, Canaani E, Arlinghaus R (1993) Tyrosine phosphorylation of p160bcr by p210bcr-abl. Blood 82:1257-1263
88. Lugo TG, Witte ON (1989) The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol 9:1263-1270
89. Maguer-Satta V, Burl S, Liu L, Damen J, Chahine H, Krystal G, Eaves A, Eaves C (1998) BCR-ABL accelerates C2-ceramide-induced apoptosis. Oncogene 16:237-248
90. Mandanas RA, Boswell HS, Lu L, Leibowitz D (1992) BCR-ABL confers growth factor independence upon a murine myeloid cell line. Leukemia 6:796-800
91. Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS (1993) Role of p21 ras in p210 bcr-abl transformation of murine mveloid cells. Blood 82:1838-1847
92. Marais R, Marshall CJ (1996) Control of the ERK MAP kinase cascade by Ras and Raf. In: Parker P, Pawson T (eds) Cell signalling. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 101-125
93. Marais R, Light Y, Paterson HF, Marshall CJ (1995) Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 14:3136-3145
94. Maru Y, Witte ON (1991) The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 67:459-468
95. Maru Y, Afar DEH, Witte ON, Shibuya M (1996) The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain. J Biol Chem 271:15353-15357
96. Maru Y, Witte ON, Shibuya M (1996) Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence. FEBS Lett 379:244-246
97. Matsuda M, Tanaka S, Nagata S, Kojima A, Kurata T, Shibuya M (1992) Two species of human CRK cDNA encode proteins with distinct biological activities. Mol Cell Biol 12:3482-3489
98. Matsuguchi T, Salgia R, Hallek M, Eder M, Druker B, Ernst TJ, Griffin JD (1994) She phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem 7:5016-5021
99. Matsuguchi T, Inborn RC, Carlesso N, Xu G, Druker B, Griffin JD (1995) Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM- CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL [see comments). Embo J 14:257-65
100. Mayer BJ, Baltimore D (1994) Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the AbI tyrosine kinase. Mol Cell Biol 14:2883-2894
101. Mayer BJ, Hamaguchi M, Hanafusa H (1988) A novel viral oncogene with structural similarity to phospholipase C. Nature 332:272-275
102. Mayer BJ, Jackson PK, Van Etten RA, Baltimore D (1992) Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol Cell Biol 12:609-618
103. Mayer BJ, Hirai H, Sakai R (1995) Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases. Curr Biol 5:296-305
104. McGlade CJ, Ellis C, Reedijk M, Anderson D, Mbamalu G, Reith AD, Panayotou G, End P, Bernstein A, Kazlauskas A, et al (1992) SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol Cell Biol 12:991-997
105. McGohan A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179-1187
106. McLaughlin J, Chianese E, Witte ON (1987) In vitro transformation of immature hematopoietic cells by the p210 BCR-ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A 84:6558-6562
107. McWhirter JR, Wang JY (1991) Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 11:1553-1565
108. McWhirter JR, Wang JYJ (1993) An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 12:1533-1546
109. McWhirter JR, Wang JYJ (1997) Effect of Bcr Sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene 15:1625-1634
110. McWhirter JR, Galasso DL, Wang JYJ (1993) A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13:7587-7595
111. Medema RH, Bos JL (1993) The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog 4:615-661
112. Meisner H, Conway BR, Hartley D, Czech MP (1995) Interactions of Cbl with Grb2 and phosphatidylinositol 3′-kinase in activated Jurkat cells. Mol Cell Biol 15:3571-3578
113. Miller JS (1998) Innovative therapy for chronic myelogenous leukemia. Hematol Oncol Clin North Am 12:173-206
114. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee C, Kuriyan J, Miller W (1997) Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385:650-653
115. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR, Witte ON (1991) BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 11:1785-1792
116. Muller AJ, Pendergast AM, Havlik MH, Puil L, Pawson T, Witte ON (1992) A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction. Mol Cell Biol 12:5087-5093
117. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempsl P, Golde DW (1994) Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 84:2912-2918
118. Nishii K, Kabarowski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF (1996) ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 13:2225-2234
119. Nojima Y, Morino N, Mimura T, Hamasaki K, Furuya H, Sakai R, Sato T, Tachibana K, Morimoto C, Yazaki Y, et al (1995) Integrin-mediated cell adhesion promotes tyrosine phosphorylation of p130Cas, a Src homology 3-containing molecule having multiple Src homology 2-binding motifs. J Biol Chem 270:15398-15402
120. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ (1994) Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269:22925-22928
121. Odai H, Sasaki K, Iwamatsu A, Hanazono Y, Tanaka T, Mitani K, Yazaki Y, Hirai H (1995) The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells. J Biol Chem 270:10800-10805
122. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedetnann LM (1995) The novel activation of Abl by fusion to an ets-related gene. TEL. Cancer Res 55:34-38
123. Pendergast AM, Muller AJ, Havlik MH, Clark R, McCormick F, Witte ON (1991) Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci U S A 88:5927-5931
124. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON (1991) BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66:161-171
125. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, et al (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175-185
126. Pleiman CM, Hertz WM, Cambier JC (1994) Activation of phosphatidylinositol-3′ kinase by Src-family kinase SH3 binding to the p85 subunit. Science 263:1609-1612
127. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T (1994) Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13:764-773
128. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL (1995) The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 92:11746-11750
129. Ramakrishnan L, Rosenberg N (1989) Abl genes. Biochim Biophys Acta 989:209-224
130. Ren R, Mayer BJ, Cicchetti P, Baltimore D (1993) Identification of a ten-amino acid proline-rich SH3 binding site. Science 259:1157-1161
131. Renshaw MW, McWhirter JR, Wang JYJ (1995) The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol 15:1286-1293
132. Rowley PT, Keng PC, Kosciolek BA (1996) The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells. Leuk Res 20:473-480
133. Sakai N, Ogiso Y, Fujita H, Watari H, Koike T, Kuzumaki N (1994) Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells. Exp Cell Res 215:131-136
134. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, Yazaki Y, Hirai H (1994) A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J 13:3748-3756
135. Salgia R, Brunkhorst B, Pisick E, Li JL, Lo SH, Chen LB, Griffin JD (1995) Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 11:1149-1155
136. Salgia R, Li JL, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, Sun Y, Pisick E, Hallek M, Ernst T, et al (1995) Molecular cloning of human paxillin, a focal adhesion protein phophorylated by p210BCR/ABL. J Biol Chem 270:5039-5047
137. Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB, et al (1995) CRKL links p210BCR/ABL with Paxillin in chronic myelogenous leukemia cells. J Biol Chem 270:29145-29150
138. Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD (1996) p130CAS forms a signaling complex with the adaptor protein CRKL in hematopoietic cells. J Biol Chem 271:25198-25203
139. Salgia R, Sattler M, Pisick E, Li JL, Griffin JD (1996) p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol 24:310-313
140. Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA, Ernst T, Sattler M, Chen LB, Griffin JD (1997) BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 100:46-57
141. Sanchez-Garcia I, Grutz G (1995) Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A 92:5287-5291
142. Sanchez-Garcia I, Martin-Zanca D (1997) Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol 267:225-228
143. Satoh T, Nakafuku M, Kaziro Y (1992) Function of Ras as a molecular switch in signal transduction. J Biol Chem 267:24149-24152
144. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD (1996) The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 12:839-846
145. Sawyers CL, Gishizky ML, Quan S, Golde DW, Witte ON (1992) Propagation of human blastic myeloid leukemias in the SCID mouse. Blood 79:2089-2098
146. Sawyers CL, McLaughlin J, Witte ON (1995) Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 181:307-313
147. Schlessinger J (1993) How receptor tyrosine kinases activate Ras. Trends Biochem Sci 18:273-275
148. Senechal K, Halpern J, Sawyers CL (1996) The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem 271:23255-23261
149. Shoelson SE, Sivaraja M, Williams KP, Schlessinger J, Weiss MA (1993) Specific phosphopeptide binding regulates a confirmational change in the PI 3-kinase SH2 domain associated with enzyme activation. EMBO J 12:795-802
150. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL (1996) Constitutive activation of STATS by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247-254
151. Sicheri F, Moarefi I, Kuriyan J (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature 385:602-609
152. Simmons PJ, Levesque JP, Zannettino AC (1997) Adhesion molecules in haemopoiesis. Baillieres Clin Haematol 10:485-505
153. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B (1995) Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726-736
154. Skorski T, Nieborowska-Skorska M, Szczylik C, Kanakaraj P, Perrotti D, Zon G, Gewirtz A, Perussia B, Calabretta B (1995) C-RAF-1 serine/threonine kinase is required in BCR/ ABL-dependent and normal hematopoiesis. Cancer Res 55:2275-2278
155. Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA, Calabretta B (1996) Blastic transformation of p53-deficient bone marrow cells by p210bcr-abl tyrosine kinase. Proc Natl Acad Sci U S A 93:13137-13142
156. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, et al (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16:6151-6161
157. Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, Salomoni P Antonyak M, Martinez R, Majewski M, et al (1998) The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood 91:406-418
158. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ, et al (1993) SH2 domains recognize specific phosphopeptide sequences. Cell 72:767-778
159. Tanaka S, Ouchi T, Hanafusa H (1997) Downstream of Crk adaptor signaling pathway: activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G. Proc Natl Acad Sci U S A 94:2356-2361
160. Taniguchi T (1995) Cytokine signaling through nonreceptor protein tyrosine kinases. Science 268:251-255
161. Tari AM, Arlinghaus R, Lopez-Berestein G (1997) Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochem Biophys Res Commun 235:383-388
162. Tauchi T, Feng GS, Shen R, Song HY, Donner D, Pawson T, Broxmeyer HE (1994) SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. J Biol Chem 269:15381-15387
163. Tauchi T, Miyazawa K, Feng GS, Broxmeyer HE, Toyama K (1997) A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. J Biol Chem 272:1389-1394
164. ten Hoeve J, Morris C, Heisterkamp N, Groffen J (1993) Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene 8:2469-2474
165. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J (1994) Tyrosine phosphorylation of CRKL in Philadelphia + leukemia. Blood 84:1731-1736
166. ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N, Groffen J (1994) Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res 54:2563-2567
167. Uemura N, Salgia R, Li JL, Pisick E, Sattler M, Griffin JD (1997) The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia 11:376-385
168. Van Etten RA, Jackson P, Baltimore D (1989) The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669-678
169. Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, Janmey PA (1994) The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J Cell Biol 124:325-340
170. Vanhaesebroeck B, Stein RC, Waterfield MD (1996) The study of phosphoinositide 3-kinase function. In: Parker P, Pawson T (eds) Cell signalling. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 249-270
171. Varticovski L, Daley GO, Jackson P, Baltimore D, Cantley LC (1991) Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 11:1107-1113
172. Verfaillie CM, Hurley R, Zhao RC, Prosper F, Delforge M, Bhatia R (1997) Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? J Lab Clin Med 129:584-591
173. Vojtek AB, Hollenberg SM, Cooper JA (1993) Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74:205-214
174. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N ( 1995) BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603-11
175. Walkenhorst J, Goga A, Witte ON, Superti-Furga G (1996) Analysis of human c-Abl tyrosine kinase activity and regulation in S. pombe. Oncogene 12:1513-1520
176. Wang J, Auger KR, Jarvis L, Shi Y, Roberts TM (1995) Direct association of Grb2 with the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 270:12774-12780
177. Warmuth M, Bergmann M, Priess A, Häuslmann K, Emmerich B, Hallek M
178. Warne PH, Viciana PR, Downward J (1993) Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364:352-355
179. Wen ST, Van Etten RA (1997) The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 11:2456-2467
180. Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R (1993) Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 92:1925-1939
181. Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB (1996) P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 56:3426-3430
182. Wilson-Rawls J, Liu J, Laneuville P, Arlinghaus RB (1997) P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2. Leukemia 11 [Suppl 3]: 428-431
183. Wisniewski D, Strife A, Clarkson B (1996) c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells. Leukemia 10:1436-1442
184. Woodgett JR, Avruch J, Kyriakis J (1996) The stress activated protein kinase pathway. In: Parker P. Pawson T (eds) Cell signalling. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 127-138
185. Young JC, Witte ON (1988) Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures. Mol Cell Biol 8:4079-4087
186. Zhu J, Shore SK (1996) c-ABL tyrosine kinase activity is regulated by association with a novel SH3-domain-binding protein. Mol Cell Biol 16:7054-7062